Pérez JA

Language: Spanish
References: 10
Page: s105-109
PDF size: 209.21 Kb.

REFERENCES

1. Mörtzell Henriksson M, Newman E, Witt V, Derfler K, Leitner G, Eloot S et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016; 54 (1): 2-15. Available in: https://linkinghub.elsevier.com/retrieve/pii/S1473050216000057

2. Almutairi H, Salam M, Batarfi K, Alharbi D, Wani F, Almutairi A et al. Incidence and severity of adverse events among platelet donors: A three-year retrospective study. Medicine (Baltimore). 2020; 99 (52): e23648.

3. Organización Panamericana de la Salud (OPS). Elegibilidad para la donación de sangre. Washington, D.C.: OPS; [ISBN: 978-92-75-32915-3], 2025. p. 45-46.

4. Cruz Roja Americana. Preguntas frecuentes sobre la donación de sangre [Internet]. Washington, D.C.: American Red Cross; c2023 [Citado 4 Ago 2025]. Disponible en: https://www.redcrossblood.org/espanol/donar-sangre/preguntas-frecuentes-sobre-la-donacion.html

5. McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion. 1998; 38 (10): 938-943.

6. Page EA, Coppock JE, Harrison JF. Study of iron stores in regular plateletpheresis donors. Transfus Med. 2010; 20 (1): 22-29.

7. Tran-Mi B, Storch H, Seidel K, Schulzki T, Haubelt H et al. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers. Vox Sang. 2004; 86 (3): 189-197.

8. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 21st ed. Strasbourg: EDQM; 2023, p. 401-404.

9. Salinas AR. La aféresis terapéutica: su papel en la medicina del siglo XXI. Rev Mex Med Transfus. 2022; 14 (s1): s30-s37.

10. Cohn CS, Delaney M, Katz LM, Schwartz J. Technical manual. 21st Ed. Bethesda, MD. USA: AABB Press; 2023.